Insmed Incorporated Company Profile (NASDAQ:INSM)

About Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated logoInsmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INSM
  • CUSIP: N/A
  • Web: www.insmed.com
Capitalization:
  • Market Cap: $997.79 million
  • Outstanding Shares: 62,090,000
Average Prices:
  • 50 Day Moving Avg: $17.65
  • 200 Day Moving Avg: $15.56
  • 52 Week Range: $9.02 - $19.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.44
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.96 per share
  • Price / Book: 8.20
Profitability:
  • EBIDTA: ($173,660,000.00)
  • Return on Equity: -52.37%
  • Return on Assets: -44.14%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 8.80%
  • Quick Ratio: 8.80%
Misc:
  • Average Volume: 304,391 shs.
  • Beta: 0.67
  • Short Ratio: 13.51
 

Frequently Asked Questions for Insmed Incorporated (NASDAQ:INSM)

What is Insmed Incorporated's stock symbol?

Insmed Incorporated trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed Incorporated's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). View Insmed Incorporated's Earnings History.

When will Insmed Incorporated make its next earnings announcement?

Insmed Incorporated is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Insmed Incorporated.

Where is Insmed Incorporated's stock going? Where will Insmed Incorporated's stock price be in 2017?

3 brokerages have issued 12-month price objectives for Insmed Incorporated's stock. Their predictions range from $24.00 to $27.00. On average, they expect Insmed Incorporated's stock price to reach $25.50 in the next year. View Analyst Ratings for Insmed Incorporated.

Who are some of Insmed Incorporated's key competitors?

Who are Insmed Incorporated's key executives?

Insmed Incorporated's management team includes the folowing people:

  • William H. Lewis, President, Chief Executive Officer, Director
  • Orlov S Nicole Schaeffer, Senior Vice President- Human Resource and Corporate Services
  • Eugene Jeffrey Sullivan M.D., Chief Product Strategy Officer and Chief Scientific Officer
  • Peggy J. Berry, Vice President- Regulatory Affairs
  • Mark Quigley, Vice President- Quality Assurance
  • Christine A. Pellizzari, General Counsel, Corporate Secretary
  • Roger Adsett, Chief Commercial Officer
  • Donald J. Hayden Jr., Non-Executive Chairman of the Board
  • Randy Whitcomb M.D., Lead Independent Director
  • David R. Brennan, Director

Who owns Insmed Incorporated stock?

Insmed Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Palo Alto Investors LLC (8.91%), Vanguard Group Inc. (6.10%), Janus Capital Management LLC (4.52%), State Street Corp (2.42%) and JPMorgan Chase & Co. (2.37%). Company insiders that own Insmed Incorporated stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden, Jr, Myrtle S Potter, Orlov S Nicole Schaeffer and William Lewis. View Institutional Ownership Trends for Insmed Incorporated.

Who sold Insmed Incorporated stock? Who is selling Insmed Incorporated stock?

Insmed Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers Inc. PA, Teachers Advisors LLC, Emerald Mutual Fund Advisers Trust, Paulson & CO. Inc., JPMorgan Chase & Co., UBS Group AG, Janus Capital Management LLC and Moody Aldrich Partners LLC. Company insiders that have sold Insmed Incorporated stock in the last year include Andrew T Drechsler, Myrtle S Potter and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed Incorporated.

Who bought Insmed Incorporated stock? Who is buying Insmed Incorporated stock?

Insmed Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., C WorldWide Group Holding A S, Palo Alto Investors LLC, State Street Corp, Pictet Asset Management Ltd., Point72 Asset Management L.P., Cornerstone Capital Management Holdings LLC. and Russell Investments Group Ltd.. Company insiders that have bought Insmed Incorporated stock in the last two years include Christine A Pellizzari and William Lewis. View Insider Buying and Selling for Insmed Incorporated.

How do I buy Insmed Incorporated stock?

Shares of Insmed Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insmed Incorporated's stock price today?

One share of Insmed Incorporated stock can currently be purchased for approximately $16.07.


MarketBeat Community Rating for Insmed Incorporated (NASDAQ INSM)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  210
MarketBeat's community ratings are surveys of what our community members think about Insmed Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insmed Incorporated (NASDAQ:INSM) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.50 (58.68% upside)

Analysts' Ratings History for Insmed Incorporated (NASDAQ:INSM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017Stifel NicolausBoost Price TargetBuy$23.00 -> $27.00MediumView Rating Details
11/4/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
8/21/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
4/17/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
3/16/2016Citigroup IncLower Price TargetNeutral$21.00 -> $13.00N/AView Rating Details
2/26/2016Leerink SwannLower Price TargetOutperform$29.00 -> $23.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Insmed Incorporated (NASDAQ:INSM)
Earnings by Quarter for Insmed Incorporated (NASDAQ:INSM)
Earnings History by Quarter for Insmed Incorporated (NASDAQ:INSM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/3/2017Q1 2017($0.60)($0.60)$0.30 millionViewListenView Earnings Details
2/23/2017Q316($0.89)($1.10)$0.30 millionViewN/AView Earnings Details
11/3/2016Q216($0.59)($0.61)$0.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.59)ViewN/AView Earnings Details
5/5/2016Q1($0.56)($0.54)ViewN/AView Earnings Details
2/25/2016Q415($0.49)($0.51)ViewN/AView Earnings Details
11/6/2015Q315($0.48)($0.50)ViewN/AView Earnings Details
8/6/2015Q2($0.48)($0.47)ViewN/AView Earnings Details
5/7/2015Q115($0.49)($0.55)ViewN/AView Earnings Details
2/27/2015Q414($0.57)($0.36)ViewN/AView Earnings Details
11/6/2014Q314($0.51)($0.54)ViewN/AView Earnings Details
8/6/2014Q214($0.50)($0.59)ViewN/AView Earnings Details
5/8/2014Q114($0.39)($0.36)ViewN/AView Earnings Details
3/6/2014Q413($0.45)($0.41)ViewN/AView Earnings Details
11/5/2013Q313($0.41)($0.46)ViewListenView Earnings Details
8/6/2013Q2 2013($0.32)($0.28)$5.38 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.46)($0.43)ViewListenView Earnings Details
11/7/2012Q312($0.42)($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insmed Incorporated (NASDAQ:INSM)
2017 EPS Consensus Estimate: ($2.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.58)($0.58)($0.58)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Insmed Incorporated (NASDAQ:INSM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Insmed Incorporated (NASDAQ:INSM)
Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 92.97%
Insider Trades by Quarter for Insmed Incorporated (NASDAQ:INSM)
Institutional Ownership by Quarter for Insmed Incorporated (NASDAQ:INSM)
Insider Trades by Quarter for Insmed Incorporated (NASDAQ:INSM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Christine A PellizzariGeneral CounselBuy20,000$12.81$256,200.00View SEC Filing  
12/14/2016Myrtle S PotterDirectorSell6,466$12.79$82,700.14View SEC Filing  
11/14/2016Andrew T DrechslerCFOSell45,000$14.67$660,150.00View SEC Filing  
11/9/2016Orlov S Nicole SchaefferSVPSell68,774$11.95$821,849.30View SEC Filing  
2/1/2016William LewisCEOBuy50,000$13.34$667,000.00View SEC Filing  
9/2/2015Donald J. Hayden, Jr.DirectorSell25,000$24.06$601,500.00View SEC Filing  
5/12/2015Mark QuigleyVPSell18,750$22.07$413,812.50View SEC Filing  
8/13/2014Melvin Md SharokyDirectorBuy88,889$11.25$1,000,001.25View SEC Filing  
11/1/2013William LewisCEOBuy5,233$14.28$74,727.24View SEC Filing  
7/22/2013Fmr LlcInsiderSell158,758$12.02$1,908,271.16View SEC Filing  
7/18/2013Fmr LlcInsiderSell310,227$11.49$3,564,508.23View SEC Filing  
7/15/2013Fmr LlcInsiderSell161,531$10.79$1,742,919.49View SEC Filing  
7/9/2013Fmr LlcInsiderSell146,599$10.01$1,467,455.99View SEC Filing  
7/3/2013Fmr LlcInsiderSell365,779$9.96$3,643,158.84View SEC Filing  
7/1/2013William LewisCEOBuy7,585$9.83$74,560.55View SEC Filing  
6/24/2013Fmr LlcInsiderSell50,000$12.00$600,000.00View SEC Filing  
6/20/2013Fmr LlcInsiderSell143,088$12.24$1,751,397.12View SEC Filing  
6/12/2013Fmr LlcInsiderSell85,758$13.00$1,114,854.00View SEC Filing  
6/6/2013Fmr LlcInsiderSell130,557$12.85$1,677,657.45View SEC Filing  
4/1/2013William LewisCEOBuy9,816$7.58$74,405.28View SEC Filing  
1/9/2013William LewisCEOBuy10,770$6.90$74,313.00View SEC Filing  
12/3/2012William LewisCEOBuy13,568$7.36$99,860.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Insmed Incorporated (NASDAQ:INSM)
Latest Headlines for Insmed Incorporated (NASDAQ:INSM)
Source:
DateHeadline
streetinsider.com logoForm 8-K INSMED Inc For: May 15 - StreetInsider.com
www.streetinsider.com - May 20 at 5:44 PM
reuters.com logoBRIEF-Insmed Inc files for potential stock shelf offering
www.reuters.com - May 19 at 5:39 PM
globenewswire.com logoInsmed Announces Key Additions to its Executive Management Team - GlobeNewswire (press release)
globenewswire.com - May 16 at 10:50 PM
americanbankingnews.com logo-$0.62 EPS Expected for Insmed Incorporated (INSM) This Quarter
www.americanbankingnews.com - May 10 at 8:36 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for Insmed Incorporated Issued By Leerink Swann (INSM)
www.americanbankingnews.com - May 8 at 8:21 AM
americanbankingnews.com logoInsmed Incorporated (INSM) Releases Earnings Results, Hits Expectations
www.americanbankingnews.com - May 5 at 11:53 PM
seekingalpha.com logoBest Biotech Stocks For Capital Gains In The Next 3 Months
seekingalpha.com - May 4 at 6:07 PM
reuters.com logoBRIEF-Insmed reports Q1 loss per share $0.60
www.reuters.com - May 4 at 6:07 PM
finance.yahoo.com logoEdited Transcript of INSM earnings conference call or presentation 3-May-17 12:30pm GMT
finance.yahoo.com - May 4 at 6:07 PM
streetinsider.com logoForm 8-K INSMED Inc For: May 03 - StreetInsider.com
www.streetinsider.com - May 4 at 12:41 AM
finance.yahoo.com logoInvestor Network: Insmed Incorporated to Host Earnings Call
finance.yahoo.com - May 4 at 12:41 AM
finance.yahoo.com logoInsmed Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 4 at 12:41 AM
finance.yahoo.com logoInsmed reports 1Q loss
finance.yahoo.com - May 4 at 12:41 AM
americanbankingnews.com logoInsmed (INSM) Given Coverage Optimism Score of 0.44
www.americanbankingnews.com - May 3 at 11:20 AM
americanbankingnews.com logoInsmed Incorporated (INSM) Given Buy Rating at Stifel Nicolaus
www.americanbankingnews.com - May 1 at 3:02 PM
americanbankingnews.com logoInsmed (INSM) Getting Positive News Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 10:51 AM
nasdaq.com logoImplied Volatility Surging for Insmed (INSM) Stock Options - Nasdaq
www.nasdaq.com - April 29 at 9:11 AM
finance.yahoo.com logoImplied Volatility Surging for Insmed (INSM) Stock Options
finance.yahoo.com - April 28 at 10:01 AM
americanbankingnews.com logoInsmed (INSM) Earning Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 27 at 9:32 PM
finance.yahoo.com logoInsmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017 - Yahoo Finance
finance.yahoo.com - April 27 at 8:48 AM
finance.yahoo.com logoInsmed to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - April 27 at 8:48 AM
americanbankingnews.com logoInsmed Incorporated (INSM) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 27 at 12:50 AM
americanbankingnews.com logoInsmed Incorporated (INSM) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 27 at 12:28 AM
finance.yahoo.com logoInsmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017
finance.yahoo.com - April 26 at 7:24 PM
americanbankingnews.com logoInsmed (INSM) Receives Daily Coverage Optimism Rating of -0.12
www.americanbankingnews.com - April 24 at 1:32 PM
nasdaq.com logoFirst Week of November 17th Options Trading For Insmed (INSM)
www.nasdaq.com - April 20 at 6:02 PM
americanbankingnews.com logoInsmed (INSM) Earning Favorable News Coverage, Study Finds
www.americanbankingnews.com - April 20 at 11:09 AM
americanbankingnews.com logoStifel Nicolaus Reiterates Buy Rating for Insmed Incorporated (INSM)
www.americanbankingnews.com - April 18 at 11:46 AM
americanbankingnews.com logoInsmed Incorporated (INSM) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 9 at 9:32 PM
nasdaq.com logoDo Options Traders Know Something About Insmed Incorporated (INSM) Stock We Don't? - Nasdaq
www.nasdaq.com - March 21 at 12:20 PM
finance.yahoo.com logoDo Options Traders Know Something About Insmed Incorporated (INSM) Stock We Don't?
finance.yahoo.com - March 21 at 12:20 PM
nasdaq.com logoNoteworthy Monday Option Activity: SMTC, ISRG, INSM
www.nasdaq.com - March 6 at 5:28 PM
globenewswire.com logoInsmed to Present at the Cowen and Company 37th Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 2 at 3:20 PM
finance.yahoo.com logoINSMED INC Financials
finance.yahoo.com - February 28 at 6:05 PM
finance.yahoo.com logoInsmed to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 9:20 AM
finance.yahoo.com logoEdited Transcript of INSM earnings conference call or presentation 23-Feb-17 1:30pm GMT
finance.yahoo.com - February 23 at 10:57 PM
biz.yahoo.com logoQ4 2016 Insmed Inc Earnings Release - Before Market Open
us.rd.yahoo.com - February 23 at 5:55 PM
us.rd.yahoo.com logoInsmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update
us.rd.yahoo.com - February 23 at 5:55 PM
biz.yahoo.com logoINSMED INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - February 23 at 5:55 PM
biz.yahoo.com logoINSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - February 23 at 5:55 PM
finance.yahoo.com logoInsmed to Host Fourth Quarter and Year-end 2016 Financial Results Conference Call on Thursday, February 23, 2017
finance.yahoo.com - February 16 at 8:09 AM
finance.yahoo.com logoInsmed Inc. Extends ARIKAYCE Intellectual Property Protection with Issuance of New U.S. Patent
finance.yahoo.com - February 14 at 7:19 PM
finance.yahoo.com logo8:07 am Insmed announces that the USPTO issued U.S. Patent Number 9,566,234 for ARIKAYCE, the Co's liposomal amikacin for inhalation
finance.yahoo.com - February 14 at 7:19 PM
thestreet.com logoFirst Week Of August 18th Options Trading For Insmed (INSM)
www.thestreet.com - January 25 at 7:23 PM
seekingalpha.com logoInsmed (INSM) Presents At 35th Annual J.P. Morgan Healthcare Conference
seekingalpha.com - January 12 at 6:25 PM
finance.yahoo.com logoInsmed to Present at the 35th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 6:50 PM
streetinsider.com logoForm 4 INSMED Inc For: Dec 14 Filed by: Pellizzari Christine A - StreetInsider.com
www.streetinsider.com - December 16 at 6:32 PM
streetinsider.com logoForm 4 INSMED Inc For: Dec 13 Filed by: POTTER MYRTLE S - StreetInsider.com
www.streetinsider.com - December 16 at 4:39 AM

Social

Chart

Insmed Incorporated (INSM) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff